BeStock  
Markets › Compare › IONS vs ERAS

IONS vs ERAS

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
IONS · Ionis Pharmaceuticals$26.58 ▼ 2.35%
ERAS · Erasca$13.61 ▼ 4.29%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

-11197406614822Nov 24, '25May 26, '26Nov 20, '26
  • IONS -66.1%
  • ERAS +370.9%

Head to head

MetricIONSERAS
Price$26.58$13.61
Change today▼ 2.35%▼ 4.29%
Market cap$4.43B$4.78B
Return, 3 months-57.2%-22.7%
Return, year to date-66.4%+265.9%
Return, 1 year-65.1%+366.1%
P/E (TTM)––
P/B11.25.2
P/E percentile vs own 5y89th12th
Dividend yield––
Revenue growth (YoY, latest qtr)+54.9%–
Net profit growth (YoY)+14.5%-67.7%
Gross margin98.2%–
Operating margin-58.8%–
Net margin-56.9%–
Return on equity-108.1%-48.7%
Analyst target vs. price+172.3%+81.3%
Analyst buy share95%67%
RSI (14)2243
30-day volatility82.9%81.2%
Max drawdown, 1 year-69.3%-59.5%
Trend readStrong downtrendStrong downtrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • ERAS is the largest of the group by market value.
  • ERAS has returned the most over the past year.
  • ERAS has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top